FDA
-
-
-
-
-
-
-
Daxor transitions to Exchange Act reporting framework
-
-
-
-
-
-
-
Daxor Corporation Unveils Next-Gen BVA Analyzer
-
-
-
-
-
-
-
Daxor receives FDA clearance for rapid blood volume analyzer
-
-
-
-
-
-
-
Three New Medical Centers Adopt Daxor's Blood Volume Diagnostic Signaling Growing Clinical Acceptance
-
-
-
-
-
-
-
Daxor Corp. (DXR) Announces New Data from Duke University and Highlights Key BVA Insights at American College of Cardiology’s 74th Annual Scientific Session and Expo
-
-
-
-
-
-
-
Daxor Corporation Reports Increase in NAV to $7.25 Per Share and 116.5 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2023
-
-
-
-
-
-
-
Daxor's Blood Volume Analysis Uncovers Hidden Heart Failure Subtype in Nearly 1 in 5 Patients, Enabling Targeted Treatment
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

